Prosecution Insights
Last updated: November 04, 2026
Application No. 17/553,462

RADIOLABELED COMPOUNDS AND USES THEREOF

Non-Final OA §103
Filed
Dec 16, 2021
Priority
Jun 20, 2019 — provisional 62/864,339 +1 more
Examiner
PERREIRA, MELISSA JEAN
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Research Foundation for Mental Hygiene, Inc.
OA Round
2 (Non-Final)
52%
Grant Probability
Moderate
2-3
OA Rounds
0m
Est. Remaining
78%
With Interview

Examiner Intelligence

Grants 52% of resolved cases
52%
Career Allowance Rate
436 granted / 837 resolved
-7.9% vs TC avg
Strong +26% interview lift
Without
With
+25.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
33 currently pending
Career history
883
Total Applications
across all art units

Statute-Specific Performance

§101
2.1%
-37.9% vs TC avg
§103
56.1%
+16.1% vs TC avg
§102
12.7%
-27.3% vs TC avg
§112
16.7%
-23.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 837 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims and Previous Objections/Rejections Status Claims 1,26,27,29,30,32-34,36 and 43 are pending in the application. Claims 2-25,28,31,35 and 37-42 are cancelled and claim 43 is added in the amendment filed 5/22/26. Any objections and/or rejections from previous office actions that have not been reiterated in this office action are obviated. New Grounds of Rejection Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 32-34 and 43 is/are rejected under 35 U.S.C. 103 as being unpatentable over Cortes- Salva et al. (Molecules 2018, 23, 2850, p1-10) in view of Mann et al. (US 2008/0138282A1) and in further view of Toyokuni et al. (WO03/089013). Cortes-Salva et al. (Molecules 2018, 23, 2850, p1-10) discloses the COX-2 inhibitor compound PNG media_image1.png 120 212 media_image1.png Greyscale (p6, scheme 1). The PNG media_image2.png 48 92 media_image2.png Greyscale encompasses the PNG media_image3.png 62 88 media_image3.png Greyscale moiety of the of the instant claims when R1 is hydrogen. The PNG media_image4.png 68 44 media_image4.png Greyscale encompasses the PNG media_image5.png 80 46 media_image5.png Greyscale moiety of the of the instant claims. The PNG media_image6.png 44 74 media_image6.png Greyscale encompasses the PNG media_image7.png 48 80 media_image7.png Greyscale moiety of the instant claims . Cortes-Salva et al. does not disclose the Me moiety of the PNG media_image8.png 26 52 media_image8.png Greyscale is 11CH3. Mann et al. (US 2008/0138282A1) discloses COX-2 compounds PNG media_image9.png 66 156 media_image9.png Greyscale wherein A is 3- to 7-membered heterocycle, etc.; R1 is 11C-labeled C1-C6- alkyl group, etc.; R2 is -aryl, etc.; and R3 is -halo, such as -F, -Cl, etc. (p2, [0011-0015]; p4, [0046]). The 3- to 7-membered heterocycle comprises pyrimidinyl, etc. that may be substituted with one or more halo groups, such as -F, -Cl, etc. (p4, [0046],[0048]). The 11C-labeled C1-C6- alkyl group comprises 11CH3, etc. (p2, [0037]) and encompasses the 11CH3 of the instant claims. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to substitute the Me of the PNG media_image8.png 26 52 media_image8.png Greyscale of Cortes-Salva et al. for 11CH3 as Mann et al. teaches of the advantage of PNG media_image10.png 50 70 media_image10.png Greyscale from a finite list of radiolabeled groups for the advantage of in vivo monitoring of COX-2 via PET (p1, [0009]) via monitor the progress or regression of an inflammatory disease (p1, [0009]). With regards to the instant claim 33, Cortes-Salva et al. does not disclose the substitution of the -F substituted on the pyrimidinyl moiety PNG media_image5.png 80 46 media_image5.png Greyscale for -Cl. Cortes-Salva et al. further discloses PNG media_image11.png 90 196 media_image11.png Greyscale (Scheme 1). Mann et al. further discloses that the 3- to 7-membered heterocycle comprises pyrimidinyl, etc. that may be substituted with one or more halo groups, such as -F, -Cl, etc. (p4, [0046],[0048]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to substitute the -F substituted on the pyrimidinyl moiety PNG media_image5.png 80 46 media_image5.png Greyscale of Cortes-Salva et al. with a -Cl as Cortes-Salva et al. discloses -Cl substitution on the pyrimidinyl moiety and Mann et al. teaches that the halo substituents, such as -F and -Cl are analogously substituted on the 3- to 7- membered heterocycle group. With regards to the instant claim 34, Cortes-Salva et al. does not disclose the substitution of the -F substituted on the pyrimidinyl moiety PNG media_image5.png 80 46 media_image5.png Greyscale for -CF3. Toyokuni et al. (WO03/089013) discloses the COX-2 inhibitor imaging probes PNG media_image12.png 200 208 media_image12.png Greyscale (abstract; p3, lines 4+; p5, lines 25+). The A moiety comprises a 6-membered ring selected from heteroaryl, such as pyrimidinyl (p3, lines 4+; p6, lines 3-4; p8, lines 26+). The R1 moiety comprises a methylsulfone (p3, line 12; p6, line 5). The R2 moiety comprises a heteroaryl group (p3, lines 13-14; p6, lines 6-7). The R3 moiety comprises a linear or branched alkyl halide, such as trifluoromethyl or a radioactive isotope, such as 18F (p3, lines 15-16; p4, line 28; p6, line 8; p11, lines 24+). The R4 comprises hydrogen (p3, line 17; p6, line 9). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to substitute the -F substituted on the pyrimidinyl moiety PNG media_image5.png 80 46 media_image5.png Greyscale of Cortes-Salva et al. with a -CF3 as Toyokuni et al. teaches that a halo substituent is analogously substituted for an alkyl halide, such as trifluoromethyl on the 6-membered heterocycle group. Claim(s) 1,26 and 29 is/are rejected under 35 U.S.C. 103 as being unpatentable over Cortes-Salva et al. (Molecules 2018, 23, 2850, p1-10). Cortes-Salva et al. (Molecules 2018, 23, 2850, p1-10) discloses the COX-2 inhibitor compound PNG media_image1.png 120 212 media_image1.png Greyscale (p6, scheme 1). Cortes-Salva et al. does not explicitly disclose the compound PNG media_image13.png 122 232 media_image13.png Greyscale of the instant claims comprising a benzylamine moiety. Cortes-Salva et al. further discloses PNG media_image14.png 108 204 media_image14.png Greyscale wherein R2 comprises 2-Thi or Ph (Table 1). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to substitute the thiophene moiety for a phenyl moiety as Cortes-Salva et al. teaches of the analogous examination of R2 phenyl and thiophene substituents, from a finite list of substituents, for the advantage of imaging COX-2 via PET (p16, 4. Conclusions). Cortes-Salva et al. does not explicitly disclose R1 is 18F. Cortes-Salva et al. further discloses that the compounds are amenable for labeling with fluorine-18 (p4, 2.1. Target Inhibitor Selection for Radioligand Development). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to substitute the -F substituted on the pyrimidinyl moiety PNG media_image4.png 68 44 media_image4.png Greyscale of Cortes-Salva et al. with 18F as Cortes-Salva et al. teaches that the COX-2 compounds are amenable for labeling with fluorine-18 for the advantage of imaging COX-2 via PET. Cortes-Salva et al. does not explicitly disclose the compound PNG media_image15.png 128 230 media_image15.png Greyscale of the instant claims wherein the benzylamine moiety is bound at the 2-position of the pyrimidinyl moiety. Cortes-Salva et al. further discloses the compound PNG media_image16.png 104 238 media_image16.png Greyscale wherein the benzylamine moiety is bound at the 2-position of the pyrimidinyl moiety (Chart 1). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to bind the benzylamine moiety at the 2-position of the pyrimidinyl moiety, as taught by Cortes-Salva et al. for the examination of various COX-2 compounds for PET imaging of COX-2. Claim(s) 1,27 and 30 is/are rejected under 35 U.S.C. 103 as being unpatentable over Cortes-Salva et al. (Molecules 2018, 23, 2850, p1-10) in view of Mann et al. (US 2008/0138282A1). Cortes-Salva et al. (Molecules 2018, 23, 2850, p1-10) discloses the COX-2 inhibitor compounds PNG media_image1.png 120 212 media_image1.png Greyscale or the compound PNG media_image16.png 104 238 media_image16.png Greyscale wherein the benzylamine moiety is bound at the 2-position of the pyrimidinyl moiety (Chart 1; (p6, scheme 1) as well as that stated above. Cortes-Salva et al. does not explicitly disclose the compounds PNG media_image17.png 124 218 media_image17.png Greyscale or PNG media_image18.png 122 226 media_image18.png Greyscale of the instant claims. Mann et al. (US 2008/0138282A1) discloses COX-2 compounds PNG media_image9.png 66 156 media_image9.png Greyscale wherein heterocycles comprise a thiazolyl or thiophene, etc. as well as that stated above. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to substitute the thiophene moiety for a thiazolyl moiety for the examination of COX-2 compounds for PET imaging of COX-2 and monitoring the progress or regression of an inflammatory disease. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to bind a thiazolyl moiety at the 2-position of the pyrimidinyl moiety, as taught by Cortes-Salva et al. of for the examination of various COX-2 compounds for PET imaging of COX-2. Claim(s) 1 and 36 is/are rejected under 35 U.S.C. 103 as being unpatentable over Mann et al. (US 2008/0138282A1). Mann et al. (US 2008/0138282A1) discloses COX-2 compounds PNG media_image9.png 66 156 media_image9.png Greyscale wherein A is 3- to 7-membered heterocycle, etc.; R1 is 18F-labeled C1-C6- alkyl group, etc.; R2 is -aryl, etc.; and R3 is -CF3, etc. (p2, [0011-0015]; p4, [0046]). The 3- to 7-membered heterocycle comprises isoxazoyl, etc. (p4, [0046],[0048]). The 18F-labeled C1-C6-alkyl group comprises -CH2CH218F, etc. (p2, [0037]). The aryl comprises phenyl, etc. (p3, [0042]). Mann et al. does not explicitly disclose the PNG media_image19.png 132 186 media_image19.png Greyscale compound of the instant claims. Mann et al. further discloses the compound PNG media_image20.png 154 192 media_image20.png Greyscale . It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to substitute the -CH218F moiety for the -CH2CH218F as Mann et al. teaches of the substitution of -CH218F for -CH2CH218F from a finite list of representative 18F-labeled C1-C6- alkyl groups. Conclusion No claims are allowed at this time. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MELISSA JEAN PERREIRA whose telephone number is (571)272-1354. The examiner can normally be reached M9-3, T9-3, W9-3, Th9-2, F9-2. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached at 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MELISSA J PERREIRA/Examiner, Art Unit 1618
Read full office action

Prosecution Timeline

Dec 16, 2021
Application Filed
Feb 23, 2026
Non-Final Rejection mailed — §103
May 22, 2026
Response Filed
Aug 10, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758660
IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN-ALPHA (FAP-ALPHA)
6y 5m to grant Granted Oct 13, 2026
Patent 12746297
RADIOFREQUENCY AMPLIFICATION BY STIMULATED EMISSION OF RADIATION VIA PARAHYDROGEN INDUCED POLARIZATION
5y 6m to grant Granted Sep 29, 2026
Patent 12734258
RADIOLIGANDS FOR PRETARGETED PET IMAGING AND METHODS OF THEIR THERAPEUTIC USE
5y 0m to grant Granted Sep 15, 2026
Patent 12714754
DELIVERY OF CYCLIC COMPOUND BY USING CARRIER
4y 12m to grant Granted Aug 25, 2026
Patent 12691068
MODULAR LIPID COMPOUNDS AND TWO- TO THREE-COMPONENT LIPID NANOPARTICLE COMPOSITIONS
2y 7m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
52%
Grant Probability
78%
With Interview (+25.7%)
3y 9m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 837 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month